Home / Business News (page 5)

Business News

Dr. Reddy’s Laboratories Announces Acquisition of ANDA Portfolio

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the …

Read More »

Gilead and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

FOSTER CITY, Calif. & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof of …

Read More »

LEO Pharma and Research Project BIOMAP: Towards Personalized Medicine for Inflammatory Skin Diseases

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key …

Read More »

Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen

AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs. Under the …

Read More »

Federal Agencies Charge 24 People in $1.2 Billion Medicare Telemedicine Fraud Scheme

One of the largest health care fraud schemes investigated by the FBI and the U.S. Department of Health and Human Services Office of the Inspector General (HHS-OIG) and prosecuted by the Department of Justice resulted in charges against 24 defendants, including the CEOs, COOs and others associated with five telemedicine …

Read More »

Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer

Concerto HealthAI announced today that they have entered into a collaboration with Pfizer to advance work in Precision Oncology using Concerto HealthAI’s eurekaHealthTM platform, artificial intelligence (AI) models and Real World Clinical Electronic Medical Record (EMR) and healthcare claims. Data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ® initiative …

Read More »

BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy

SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) — BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted …

Read More »

Alnylam and Regeneron Partner for RNAi Therapeutics Focused on Ocular and Central Nervous System Diseases

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), announced today a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous …

Read More »

Merrimack Discontinues Development of its Investigational Solid Tumor Candidate MM-310

CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. This decision was the result of a comprehensive review of available safety data …

Read More »

Acceleron Discontinues Development of its Phase 1 Neuromuscular Disorders Molecule ACE-2494

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been studying in a Phase 1 healthy volunteer trial for …

Read More »